Epstein Secrets

From: "Jeffrey E." <[email protected]> To: Richard Kahn Subjec

From: "Jeffrey E." <[email protected]> To: Richard Kahn Su

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is - 16% of sales, ^21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in

<[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 Aug 2016 16:36:10 +0000 Dumb On Thursday, 25 August 2016, jeffrey E. <[email protected]> wrote: no On Thu, Aug 25, 2016 at 11:34 AM, Richard Kahn < > wrote: amanda is recommending we add to the two convertible pr

From: "Jeffrey E." <[email protected]> To: Richard Kahn Sub

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is —16% of sales, —21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in c

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subject: Re: Add to

h Floor New York, NY 10022 tel faxcell On Aug 25, 2016, at 12:36 PM, jeffrey E. [email protected]> wrote: Dumb On Thursday, 25 August 2016, jeffrey E. <[email protected]> wrote: no On Thu, Aug 25, 2016 at 11:34 AM, Richard Kahn • > wrote: amanda is recommending we add to the two convertible pre

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is —16% of sales, —21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in